Written by: Rick Jongerius

Tagworks Highlighted in Nature Biotechnology

We’re proud to share that Nature Biotechnology has published a new article featuring an interview with our CEO, Marc Robillard. The article includes a dedicated section on Tagworks, beginning on page three and continuing into page four. We invite you to read the full article via this link.
May 23, 2025

Tagworks to present at the J&J R&D Symposium on Antibody Conjugates

On June 19th, 2025, Marc Robillard will give a presentation about Tagworks’ Click-to-Release platform for ADCs and targeted radiotherapies at the Johnson & Johnson R&D Symposium on Antibody Conjugates in Beerse, Belgium. At this symposium exciting advancements in discovery and development of antibody-drug conjugates and targeted radiotherapies are explored by …
May 16, 2025

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer 

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.
April 22, 2025

Tagworks Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors
March 25, 2025

Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
October 1, 2024

Tagworks appoints Krisztina Nemenyi as Vice President Regulatory Affairs

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.
September 9, 2024

Tagworks lands $65M for its take on Nobel-winning click chemistry in bid to expand ADC, radiopharma potential

A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.
June 22, 2023

Tagworks’ click-to-release ADC approach draws $65M in series A round

By BioWorld Twelve years on from spinning out of Philips Healthcare, Tagworks Pharmaceuticals BV has raised $65 million in a series A round to take a new generation of antibody-drug conjugates (ADCs) based on click chemistry into the clinic. Read more.
June 22, 2023

Tagworks: using click chemistry to make ADCs more applicable and radiotherapies safer

By BioCentury Netherlands-based Tagworks is using click chemistry to simultaneously accomplish on-target activation of ADCs and off-target deactivation of radiopharmaceuticals. After spinning out of Philips Healthcare in 2011, the company has announced a $65 million series A round co-led by Ysios Capital and Gilde Healthcare. Download the complete article here.
June 22, 2023

Curious about what we do? Get in touch!

Logo-2

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2025 | Terms of use | Privacy StatementDesign by Ape to Zebra